Cargando…

Aseptic pleocytosis eight days after the first dose of a vector-based SARS-CoV-2 vaccine

OBJECTIVES: Vaccination against SARS-CoV-2 is considered beneficial by the majority, but side effects occur in some cases. RESULTS AND CONCLUSIONS: We report on a 28-year-old female who developed fever within 3 days of an initial dose with a vector-based SARS-CoV-2 vaccine. Eight days after vaccinat...

Descripción completa

Detalles Bibliográficos
Autor principal: Finsterer, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific Scholar 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945238/
https://www.ncbi.nlm.nih.gov/pubmed/36891100
http://dx.doi.org/10.25259/JNRP-2022-4-25-(2542)
_version_ 1784892096132415488
author Finsterer, Josef
author_facet Finsterer, Josef
author_sort Finsterer, Josef
collection PubMed
description OBJECTIVES: Vaccination against SARS-CoV-2 is considered beneficial by the majority, but side effects occur in some cases. RESULTS AND CONCLUSIONS: We report on a 28-year-old female who developed fever within 3 days of an initial dose with a vector-based SARS-CoV-2 vaccine. Eight days after vaccination, she developed paresthesias and dysesthesias of all four limbs. Cerebral imaging showed two non-specific and non-enhancing lesions in the left white matter. Cerebrospinal fluid (CSF) studies revealed pleocytosis of 82/3 cells. Examination for multiple sclerosis, neuromyelitis optica, acute, demyelinating encephalomyelitis, and Guillain-Barre syndrome was negative. She received steroids, which resulted in complete resolution of the neurological abnormalities. In summary, SARS-CoV-2 vaccination can occasionally be complicated by an inflammatory CSF syndrome, which resolves on administration of steroids.
format Online
Article
Text
id pubmed-9945238
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Scientific Scholar
record_format MEDLINE/PubMed
spelling pubmed-99452382023-03-07 Aseptic pleocytosis eight days after the first dose of a vector-based SARS-CoV-2 vaccine Finsterer, Josef J Neurosci Rural Pract Brief Report OBJECTIVES: Vaccination against SARS-CoV-2 is considered beneficial by the majority, but side effects occur in some cases. RESULTS AND CONCLUSIONS: We report on a 28-year-old female who developed fever within 3 days of an initial dose with a vector-based SARS-CoV-2 vaccine. Eight days after vaccination, she developed paresthesias and dysesthesias of all four limbs. Cerebral imaging showed two non-specific and non-enhancing lesions in the left white matter. Cerebrospinal fluid (CSF) studies revealed pleocytosis of 82/3 cells. Examination for multiple sclerosis, neuromyelitis optica, acute, demyelinating encephalomyelitis, and Guillain-Barre syndrome was negative. She received steroids, which resulted in complete resolution of the neurological abnormalities. In summary, SARS-CoV-2 vaccination can occasionally be complicated by an inflammatory CSF syndrome, which resolves on administration of steroids. Scientific Scholar 2023-01-27 2023 /pmc/articles/PMC9945238/ /pubmed/36891100 http://dx.doi.org/10.25259/JNRP-2022-4-25-(2542) Text en © 2023 Published by Scientific Scholar on behalf of Journal of Neurosciences in Rural Practice https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Brief Report
Finsterer, Josef
Aseptic pleocytosis eight days after the first dose of a vector-based SARS-CoV-2 vaccine
title Aseptic pleocytosis eight days after the first dose of a vector-based SARS-CoV-2 vaccine
title_full Aseptic pleocytosis eight days after the first dose of a vector-based SARS-CoV-2 vaccine
title_fullStr Aseptic pleocytosis eight days after the first dose of a vector-based SARS-CoV-2 vaccine
title_full_unstemmed Aseptic pleocytosis eight days after the first dose of a vector-based SARS-CoV-2 vaccine
title_short Aseptic pleocytosis eight days after the first dose of a vector-based SARS-CoV-2 vaccine
title_sort aseptic pleocytosis eight days after the first dose of a vector-based sars-cov-2 vaccine
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945238/
https://www.ncbi.nlm.nih.gov/pubmed/36891100
http://dx.doi.org/10.25259/JNRP-2022-4-25-(2542)
work_keys_str_mv AT finstererjosef asepticpleocytosiseightdaysafterthefirstdoseofavectorbasedsarscov2vaccine